Optimer Pharmaceuticals Price / Sales Ratio: 7.84
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OPTR Price / Sales Ratio Rankings
| Overall | 6th percentile | 4100 of 4365 |
| Sector | 21st percentile | 357 of 457 in Healthcare |
| Industry | 45th percentile | 67 of 124 in Biotechnology |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these OPTR related companies
OPTR News
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 01, 8:00AM PR Newswire
Feb 01, 8:00AM PR Newswire
RT @ReformedBroker: THE GOOD LEADS NUMERO 300! http://stks.co/1tYO @gtotoy @chessnwine @shiraovide @registered_rep $OPTR $LVS $V $MA
about 31 days ago by gtotoy
about 31 days ago by gtotoy
THE GOOD LEADS NUMERO 300! http://stks.co/1tUT starring @gtotoy @chessnwine @shiraovide @registered_rep $OPTR $LVS $V $MA
about 31 days ago by reformedbroker
about 31 days ago by reformedbroker
NEW POST: "Stock Trading Ideas and Explanations" http://stks.co/1tCw $EGLE $OPTR $SRDX $$WGO $X
about 31 days ago by chessNwine
about 31 days ago by chessNwine
RT @TER_Intraday $MTZ $BAX $DO $ANR $OPTR $OVTI $JEF all threatening range breaks.
about 32 days ago by 1nvestor
about 32 days ago by 1nvestor
Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
Jan 09, 8:00AM PR Newswire
Jan 09, 8:00AM PR Newswire
Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); 2012 Preview
Jan 06, 10:34AM Street Insider
Jan 06, 10:34AM Street Insider
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 03, 8:00AM PR Newswire
Jan 03, 8:00AM PR Newswire
Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 03, 8:00AM PR Newswire
Jan 03, 8:00AM PR Newswire
$OPTR 200 Day SMA Cross - Price crossed below 200 day SMA (12.1869). Confirmed by volume.
about 53 days ago by TradeIdeasQuant
about 53 days ago by TradeIdeasQuant
$OPTR http://stks.co/1dAn Trend line and 50 SMA break at 12.60 area. Worth watching.23% Short.
about 53 days ago by szaman
about 53 days ago by szaman
FMR LLC Raises Stake in Optimer Pharmaceuticals, Inc. (OPTR) to 12.93%
Dec 12, 11:30AM Street Insider
Dec 12, 11:30AM Street Insider
Optimer's DIFICLIR granted European Commission marketing authorization for CDI
Dec 12, 8:30AM theflyonthewall.com
Dec 12, 8:30AM theflyonthewall.com
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OPTR | 13.54 | 0.25 | 1.88% | 630.96M |
| RVBD | 27.67 | -0.06 | -0.22% | 4.30B |
| FRED | 14.73 | -0.22 | -1.47% | 567.69M |
| AKAM | 38.43 | 0.37 | 0.97% | 6.90B |
| ASEI | 77.02 | 8.74 | 12.80% | 687.02M |
| ENSG | 26.48 | -0.52 | -1.93% | 555.55M |
| EXPE | 33.54 | -0.62 | -1.81% | 4.48B |
| DGII | 11.86 | -0.27 | -2.23% | 304.09M |
| NVAX | 1.35 | -0.06 | -4.26% | 155.41M |
| AMD | 7.05 | -0.19 | -2.62% | 4.91B |
